Urine Osmolality in Treatment-naive HIV-positive Subjects in Southeast Nigeria

被引:0
|
作者
Anyabolu, E. N. [1 ,2 ,5 ]
Chukwuonye, I. I. [2 ,3 ]
Ezeani, I. [4 ]
机构
[1] Imo State Univ, Teaching Hosp, Dept Med, Div Nephrol, Orlu, Nigeria
[2] Fed Med Ctr, Dept Med, Div Nephrol, Owerri, Imo State, Nigeria
[3] Fed Med Ctr, Dept Med, Div Nephrol, Umuahia, Abia State, Nigeria
[4] Fed Med Ctr, Dept Med, Div Endocrinol, Umuahia, Abia State, Nigeria
[5] Chukwuemeka Odumegwu Ojukwu Univ, Teaching Hosp, Dept Med, Div Nephrol, Awka, Nigeria
关键词
Dilute and concentrated urine; dyslipidemia; HIV; low CD4 cells count; Nigeria; underweight and obesity; urine osmolality; RENAL-FUNCTION; KIDNEY-DISEASE; VASOPRESSIN; SODIUM; LEVEL; RISK; UREA;
D O I
10.4103/njcp.njcp_253_16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Urine osmolality varies over a wide range of values in a healthy state. Dilute urine or concentrated urine may be observed in many environmental, physiologic, and disease conditions. Urine osmolality is not commonly evaluated in routine clinical practice and in human immunodeficiency virus (HIV) subjects. The factors that influence urine osmolality have not been completely identified. The aim of this study was to evaluate urine osmolality in treatment-naive HIV subjects and to identify the factors that may influence dilute and concentrated urine in this group of patients. Methodology: This was a cross-sectional study of treatment-naive HIV subjects conducted in Federal Medical Centre (FMC), Owerri, Nigeria. Demographic and anthropometric data were obtained. Urine osmolality and other relevant investigations were conducted. Normal urine osmolality was defined as 24-h urine osmolality (24 HUOsm) 300-750 mOsm/kgH(2)O, dilute urine as 24 HUOsm <300 mOsm/kgH(2)O and concentrated urine as 24 HUOsm >750 mOsm/kgH(2)O. The association between the variables and urine osmolality and the strength of variables to predict dilute urine and concentrated urine were determined. Results: The mean 24HUOsm was 564 +/- 501 mOsm/kgH(2)O and the mean spot urine osmolality (SUOsm) 464 +/- 271 mOsm/kgH(2)O. Normal urine osmolality was observed in 29.6%, dilute urine in 64.5%, and concentrated urine in 5.9% of the HIV subjects. There was a significant association between urine osmolality and body mass index (BMI), creatinine clearance, as well as serum cholesterol level. Only high-density lipoprotein cholesterol (HDL) predicted dilute urine, whereas BMI, spot urine protein, 24-h urine protein, spot urine creatinine, serum HDL, and CD4 cell count predicted concentrated urine. Conclusion: The prevalence of dilute urine was high among the treatment-naive HIV subjects. Abnormalities of serum lipids, renal function, and weight were common in treatment-naive HIV subjects who had dilute urine. There is a need for clinicians to routinely assess urine osmolality and further diagnose for dyslipidemia, renal function impairment, and abnormal weight in HIV subjects at the early stage of the infection.
引用
下载
收藏
页码:936 / 942
页数:7
相关论文
共 50 条
  • [21] Comparison of Antiretroviral Therapy Regimens in Terms of Virological Response, Immunological Response and Adverse Effects in Treatment-Naive HIV-Positive Patients
    Benli, Aysun
    Basaran, Seniha
    Simsek-Yavuz, Serap
    Cagatay, Atahan
    Oncul, Oral
    Ozsut, Halit
    Eraksoy, Haluk
    KLIMIK JOURNAL, 2018, 31 (02) : 94 - 100
  • [22] Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients
    Maggiolo, Franco
    Roat, Erika
    Pinti, Marcello
    Nasi, Milena
    Gibellini, Lara
    De Biasi, Sara
    Airoldi, Monica
    Ravasio, Veronica
    Mussini, Cristina
    Suter, Fredy
    Cossarizza, Andrea
    ANTIVIRAL THERAPY, 2010, 15 (01) : 51 - 59
  • [23] Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naive patients in public-sector clinics in the Eastern Cape
    Gaida, Razia
    Truter, Ilse
    Grobler, Christoffel
    SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2016, 17 (01)
  • [24] Anti-HIV activity of DAPD monotherapy in treatment-naive and treatment-experienced subjects
    Raffi, F
    Kessler, H
    Thompson, M
    Eron, J
    Jacobson, J
    Arduino, R
    Torriani, F
    Deeks, S
    Sereni, D
    Sista, N
    Harris, J
    DeMasi, R
    Bigley, J
    Rousseau, F
    AIDS, 2000, 14 : S18 - S18
  • [25] Olfactory function in HIV-positive subjects
    Mueller, C
    Temmel, AFP
    Quint, C
    Rieger, A
    Hummel, T
    ACTA OTO-LARYNGOLOGICA, 2002, 122 (01) : 67 - 71
  • [26] Determinants of blood telomere length in antiretroviral treatment-naive HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial
    Alejos, B.
    Stella-Ascariz, N.
    Montejano, R.
    Rodriguez-Centeno, J.
    Schwimmer, C.
    Bernardino, J. I.
    Rodes, B.
    Esser, S.
    Goujard, C.
    Sarmento-Castro, R.
    De Miguel, R.
    Esteban-Cantos, A.
    Wallet, C.
    Raffi, F.
    Arribas, J. R.
    HIV MEDICINE, 2019, 20 (10) : 691 - 698
  • [27] Folliculitis and renewed immunocompetence in HIV-positive subjects after antiretroviral treatment
    不详
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2001, 128 (04): : 579 - 579
  • [28] Direct observation therapy in HIV-positive subjects
    Sisti, M
    Buono, M
    AIDS AND RELATED SYNDROMES, 2001, : 339 - 342
  • [29] HIV-1 genotypic resistance in treatment-naive subjects enrolled in an observational trial (GAIN)
    Becker, MI
    Haubrich, R
    Wesselman, CW
    Garrett, L
    Lee, SY
    Millard, D
    Baxter, JD
    ANTIVIRAL THERAPY, 2002, 7 : S175 - S175
  • [30] Syphilitic and cryptococcal meningoencephalitis in HIV-positive subjects
    Jolobe, O. M. P.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2020, 113 (05) : 373 - 374